ALK-B.CO Stock - ALK-Abelló A/S
Unlock GoAI Insights for ALK-B.CO
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $5.54B | $4.82B | $4.51B | $3.92B | $3.49B |
| Gross Profit | $3.55B | $3.04B | $2.79B | $2.40B | $2.03B |
| Gross Margin | 64.2% | 62.9% | 61.9% | 61.2% | 58.1% |
| Operating Income | $1.09B | $666.00M | $470.00M | $292.00M | $150.00M |
| Net Income | $815.00M | $486.00M | $335.00M | $219.00M | $25.00M |
| Net Margin | 14.7% | 10.1% | 7.4% | 5.6% | 0.7% |
| EPS | $3.68 | $2.20 | $1.52 | $1.00 | $0.11 |
ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. It product portfolio include GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDACURE, and ITULAZAX for treatment of allergic rhinitis and allergic asthma. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including grass, ragweed, house dust mite, Japanese cedar, tree, and food. It also provides consumer healthcare solution, which include Digital eco-system, a platform which connect and engages with allergy sufferers much earlier in the disease journey through tools and e-commerce offerings that supports, guidance and relief, and smoothing the path to allergy immunotherapy treatment. In addition, the company offers diagnostic allergy solutions through testing by skin prick test or blood test; and emergency treatment, such as intramuscular injection of adrenaline for the treatment of acute life-threatening allergic reactions including Anaphylaxis. ALK-Abelló A/S was founded in 1923 and is headquartered in Hørsholm, Denmark.
Visit WebsiteEarnings History & Surprises
ALK-B.COEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 4, 2026 | — | — | — | — |
Q1 2026 | Feb 17, 2026 | — | — | — | — |
Q4 2025 | Nov 12, 2025 | $1.01 | $1.41 | +39.6% | ✓ BEAT |
Q3 2025 | Aug 21, 2025 | $1.31 | $1.21 | -7.6% | ✗ MISS |
Q2 2025 | May 6, 2025 | $1.30 | $1.60 | +23.1% | ✓ BEAT |
Q1 2025 | Feb 19, 2025 | $1.00 | $0.78 | -22.0% | ✗ MISS |
Q4 2024 | Nov 14, 2024 | $0.90 | $1.06 | +17.8% | ✓ BEAT |
Q3 2024 | Aug 22, 2024 | $0.60 | $0.90 | +50.0% | ✓ BEAT |
Q2 2024 | May 2, 2024 | $1.00 | $1.10 | +10.0% | ✓ BEAT |
Q1 2024 | Feb 8, 2024 | $0.76 | $0.70 | -7.5% | ✗ MISS |
Q4 2023 | Nov 15, 2023 | $0.37 | $0.50 | +36.4% | ✓ BEAT |
Q3 2023 | Aug 24, 2023 | $0.26 | $0.30 | +15.4% | ✓ BEAT |
Q2 2023 | May 9, 2023 | $0.91 | $0.70 | -23.1% | ✗ MISS |
Q1 2023 | Feb 3, 2023 | $0.36 | $0.35 | -2.8% | ✗ MISS |
Q4 2022 | Nov 10, 2022 | $0.16 | $0.23 | +43.8% | ✓ BEAT |
Q3 2022 | Aug 11, 2022 | $0.06 | $0.19 | +216.7% | ✓ BEAT |
Q2 2022 | May 12, 2022 | $0.65 | $0.74 | +13.8% | ✓ BEAT |
Q1 2022 | Feb 8, 2022 | $0.20 | $0.35 | +75.0% | ✓ BEAT |
Q4 2021 | Nov 11, 2021 | $0.04 | $0.17 | +286.4% | ✓ BEAT |
Q3 2021 | Aug 11, 2021 | $-0.02 | $-0.09 | -400.0% | ✗ MISS |
Latest News
Frequently Asked Questions about ALK-B.CO
What is ALK-B.CO's current stock price?
What is the analyst price target for ALK-B.CO?
What sector is ALK-Abelló A/S in?
What is ALK-B.CO's market cap?
Does ALK-B.CO pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to ALK-B.CO for comparison